← brief for 2026-10-02 · Slowing decline

Elranatamab in relapsed/refractory multiple myeloma patients on hemodialysis: A real-world case series.

Key takeaways

This report looks at four people on dialysis who took a new cancer drug. It is a case series, which is a small group of real-world patients. There are no results yet from a large trial.

Who did this work

Batgi H (Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey.) · Dilan Köseoğlu F (Department of Hematology, Faculty of Medicine, Bakırçay University, Izmir, Turkey.) · Çetin D (Department of Hematology, Ege University School of Medicine, Izmir, Turkey.) · Başcı S (Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey.) · Namdaroğlu S (Dokuz Eylul University, Faculty of Medicine, Department of Hematology and Bone Marrow Transplantation Unit, Department of Hematology, Izmir, Turkey.) · Akad Soyer N (Department of Hematology, Ege University School of Medicine, Izmir, Turkey.)

Source

Paper · Europe PMC, CKD · 2026-09-28
https://doi.org/10.46989/001c.171328